Bifogade filer
PDF
Kurs
+5,07%
Likviditet
0,23 MSEK
Kalender
| Tid* | ||
| 2025-11-27 | 15:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-29 | 15:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | 15:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-28 | 16:30 | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-15 | - | Årsstämma |
| 2024-03-22 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2024-03-01 | - | Bokslutskommuniké 2023 |
| 2023-11-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | Årsstämma |
| 2023-05-12 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-25 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2023-02-10 | - | Bokslutskommuniké 2022 |
| 2022-11-18 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-25 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2022-03-24 | - | Årsstämma |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-12-30 | - | Extra Bolagsstämma 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-18 | - | Årsstämma |
| 2021-03-08 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2021-02-12 | - | Bokslutskommuniké 2020 |
| 2020-11-26 | - | Kvartalsrapport 2020-Q3 |
| 2020-11-02 | - | Extra Bolagsstämma 2020 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-29 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2020-04-24 | - | Årsstämma |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-12-18 | - | Extra Bolagsstämma 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-29 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2019-04-26 | - | Årsstämma |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-27 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-23 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2018-04-20 | - | Årsstämma |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-28 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-02 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2017-05-29 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-26 | - | Årsstämma |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-01 | - | X-dag ordinarie utdelning KLAR 0.00 SEK |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-29 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
At the extraordinary general meeting held in Klaria Pharma Holding AB (publ) today on 30 November 2022, it was resolved to approve the board of directors' resolution on issuance of shares with preferential rights for the shareholders (in accordance with the proposal presented in the notice to attend the meeting kept available at the company's website www.klaria.com).
The extraordinary general meeting resolved to approve the board of directors' resolution made on 14 November 2022 on issuance of shares with preferential rights for the shareholders. As announced on 14 November 2022, the terms of the rights issue resolved by the board of directors entail that each existing share in the company held on the record date December 5, 2022, entitles to one (1) subscription right and one (1) subscription right entitles to subscription for one (1) new share. The rights issue comprises a maximum of 59,166,957 new shares, entailing that the company's share capital may increase by a maximum of SEK 986,115.967762.
The subscription price amounts to SEK 1.25 per share. Through the rights issue, the company can receive proceeds amounting to a maximum of approximately SEK 74.0 million before issuing costs, which are estimated to amount to approximately SEK 10.5 million. The subscription period runs during December 7 - 21, 2022. Additional information regarding the rights issue will be available in the EU growth prospectus which is expected to be published around December 2, 2022.
Stockholm, November 2022
Klaria Pharma Holding AB (publ)
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com (scott.boyer@klaria.com)
Tel: +46 (0) 8-446 42 99